Top Analyst Upgrades and Downgrades: Altice, Blue Apron, CubeSmart, Horizon Pharma, KB Home, Las Vegas Sands, Mylan, Switch and More

Print Email

The futures once again looked lower Thursday morning as investors remain concerned about bellwether tech stocks breaking down and oil entering into a bear market. Many market pundits remain bullish on the possibility of a seasonal run to the year’s end, but now the possibility of a retest of the October low looms larger.

The trend of buying the dips has not worked well in 2018 as it has in prior years, and many investors have been considering how they want their investments positioned for 2019 and beyond.

24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new investing and trading ideas for our readers. Some of the top analyst reports cover stocks to buy. Others cover stocks to sell or avoid.

Additional color and commentary has been added on some of these daily analyst calls. The consensus analyst price target data are from the Thomson Reuters sell-side research service.

These were the top analyst upgrades, downgrades and other research calls from Wednesday, November 14, 2018.

Altice USA Inc. (NYSE: ATUS) was started with a Buy rating and a $26 price target at UBS. That compares with the Wall Street consensus target price of $25.18. The shares ended Wednesday’s trading at $17.71.

Athenix Inc. (NASDAQ: ATNX) was raised to Overweight from Neutral at JPMorgan. The stock has a 52-week trading range of $9.83 to $20.90 and a consensus price target of $28.99. The stock closed on Wednesday at $10.24, down over 12% on the day.

Blue Apron Inc. (NASDAQ: APRN) was downgraded to Neutral from Buy at Guggenheim. The shares have traded between $1.02 and $4.56 over the past year, and the consensus price objective is $2.28. The stock closed Wednesday at $1.17.

CubeSmart (NYSE: CUBE) was raised to Buy from Neutral at Merrill Lynch. The 52-week trading range is $25.22 to $33.18. The consensus price target is $30.67. Shares closed Wednesday at $29.75.

Horizon Pharma PLC (NASDAQ: HZNP) was downgraded to Neutral from Buy at Mizuho. The 52-week range is $12.55 to $23.38, and the consensus price target is $25.55. Shares closed Wednesday at $21.24.

KB Home (NYSE: KBH) was downgraded to Neutral from Buy at Merrill Lynch. It has a 52-week range of $18.54 to $38.80 and a consensus analyst target of $26.06. The stock closed Wednesday at $20.80 but traded down almost 9% in the premarket action.

Las Vegas Sands Inc. (NYSE: LVS) was started with an Outperform rating at Bernstein. The 52-week range is $49.28 to $81.45. The consensus price target is $67.38, and the stocked closed Wednesday at $52.48.

Loxo Oncology Inc. (NASDAQ: LOXO) was started with a Strong Buy rating and a $235 price objective at Raymond James. The consensus target is $201.50, and shares closed Wednesday at $143.42, down almost 10%.

Mylan N.V. (NASDAQ: MYL) was raised to Buy from Hold at Argus. The 52-week range is $30.33 to $47.82, and the consensus price target is $44.63. The generic drug giant’s shares closed Wednesday at $34.23, down over 4%. They traded higher in Thursday’s premarket.

Switch Inc. (NYSE: SWCH) was raised to Strong Buy from Market Perform at Raymond James. It has a 52-week range of $7.00 to $19.49 and a consensus price target of $11.94. The stock was pounded on Wednesday, closing at $7.07 down almost 24%, but shares traded almost 5% higher in the premarket.

Other key analysts upgrades and downgrades were seen in the following:

Albemarle Corp. (NYSE: ALB) was started with a Neutral rating and a $106 target at Buckingham Research. The consensus estimate is $125.45, and the stock closed at $99.94.

Copa Holdings S.A. (NYSE: CPA) was downgraded to Neutral from Buy at Citigroup. The 52-week range is $67.38 to $141.34, and the consensus price target is $105.54. The ended Wednesday at $81.41 but were down almost 5% in premarket trading.

Coty Inc. (NYSE: COTY) was raised to Outperform from Market Perform at BMO Capital Markets. The consensus price target is $10.57, and the 52-week range is $8.16 to $21.68. The stock closed at $8.70.

Denali Therapeutics Inc. (NASDAQ: DNLI) was started as Overweight with a $25 price target at Cantor Fitzgerald. The consensus price target is $24.50. Shares were last seen at $17.49.

Ocular Therapeutix Inc. (NASDAQ: OCUL) was started with a strong Buy rating and a $10 price objective at Raymond James. The consensus target is $13.33. The stock closed at $5.04, down almost 5% on Wednesday.

Realty Income Corp. (NYSE: O) was raised to Buy from Neutral at Merrill Lynch. The stock has traded between $47.25 and $63.50 over the past year, and the consensus price target is $61.14. Wednesday’s close was $63.17 a share.

In case you missed it, Wednesday’s top analyst upgrades and downgrades¬†included Alphabet, Amarin, Apple, AutoNation, BlackRock, E*Trade, Etsy, Kellogg, PG&E and more.